• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table 18Statistically significant differences in serious adverse events

DrugComparator drugOdds ratio (95% confidence interval)
Abataceptcertolizumab0.45 (95% CI, 0.24 to 0.82)
Abataceptetanercept0.53 (95% CI, 0.32 to 0.88)
Abataceptinfliximab0.50 (95% CI, 0.31 to 0.82)
Abataceptrituximab0.59 (95% CI, 0.36 to 0.98)
Abatacepttocilizumab0.52 (95% CI, 0.27 to 0.99)
AnakinraCertolizumab0.38 (95% CI, 0.18 to 0.82)
AnakinraEtanercept0.45 (95% CI, 0.22 to 0.91)
AnakinraInfliximab0.43 (95% CI, 0.21 to 0.86)
AnakinraTocilizumab0.44 (95% CI, 0.20 to 0.99)

From: RESULTS

Cover of Drug Class Review: Targeted Immune Modulators
Drug Class Review: Targeted Immune Modulators: Final Update 3 Report [Internet].
Thaler KJ, Gartlehner G, Kien C, et al.
Portland (OR): Oregon Health & Science University; 2012 Mar.
Copyright © 2012, Oregon Health & Science University, Portland, Oregon.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.